文献速递银屑病与炎症性皮肤病毛发、甲与色素性疾病

外用糖皮质激素联合家用窄谱UVB治疗活动性局限性白癜风的随机对照试验

Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial.
PubMed 文献 · Br J Dermatol · 2020-12-28

单用NB-UVB并不优于TCS。联合治疗相对安全,但仅约四分之一患者获得治疗成功。

要点

  • 联合治疗优于单用TCS,NNT=10
  • 单用NB-UVB不优于TCS
  • 仅约四分之一患者治疗成功

核心结论

  • 家用NB-UVB联合TCS治疗局限性白癜风可能优于单用TCS,单用NB-UVB不优于TCS。
  • 联合治疗相对安全且耐受良好,但仅约四分之一参与者获得治疗成功。

研究设计与样本

  • 实用性、三臂、安慰剂对照随机对照试验,治疗9个月、随访12个月。
  • 共517例(TCS组173例、NB-UVB组169例、联合组175例),来自二级医疗和社区,年龄≥5岁,活动性白癜风累及<10%皮肤。

主要发现

  • 9个月时目标皮损治疗成功比例:TCS组17%、NB-UVB组22%、联合组27%。
  • 干预预期依从性≥75%的参与者更易获得治疗成功,但治疗停止后效果消失。

关键数值与推荐

  • NB-UVB用法:隔日一次,剂量递增并根据红斑调整。
  • 主要结局:9个月时目标皮损治疗成功,采用参与者报告的Vitiligo Noticeability Scale评估,缺失数据用多重插补。
  • 试验注册号ISRCTN17160087,注册日期2015年1月8日。

临床怎么用

  • 对活动性局限性白癜风可考虑家用NB-UVB联合TCS治疗,但需告知成功率有限。
  • 治疗获益可能依赖较高依从性(预期依从性≥75%),且停药后效果消失。
  • 需监测局部红斑和皮肤变薄等不良反应。

局限性

  • 主要结局数据仅370例(72%)可获得。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence for the effectiveness of vitiligo treatments is limited. OBJECTIVES: To determine the effectiveness of (i) handheld narrowband UVB (NB-UVB) and (ii) a combination of potent topical corticosteroid (TCS) and NB-UVB, compared with TCS alone, for localized vitiligo. METHODS: A pragmatic, three-arm, placebo-controlled randomized controlled trial (9-month treatment, 12-month follow-up). Adults and children, recruited from secondary care and the community, aged ≥ 5 years and with active vitiligo affecting < 10% of skin, were randomized 1 : 1 : 1 to receive TCS (mometasone furoate 0·1% ointment + dummy NB-UVB), NB-UVB (NB-UVB + placebo TCS) or a combination (TCS + NB-UVB). TCS was applied once daily on alternating weeks; NB-UVB was administered on alternate days in escalating doses, adjusted for erythema. The primary outcome was treatment success at 9 months at a target patch assessed using the participant-reported Vitiligo Noticeability Scale, with multiple imputation for missing data. The trial was registered with number ISRCTN17160087 on 8 January 2015. RESULTS: In total 517 participants were randomized to TCS (n = 173), NB-UVB (n = 169) and combination (n = 175). Primary outcome data were available for 370 (72%) participants. The proportions with target patch treatment success were 17% (TCS), 22% (NB-UVB) and 27% (combination). Combination treatment was superior to TCS: adjusted between-group difference 10·9% (95% confidence interval 1·0%-20·9%; P = 0·032; number needed to treat = 10). NB-UVB alone was not superior to TCS: adjusted between-group difference 5·2% (95% CI - 4·4% to 14·9%; P = 0·29; number needed to treat = 19). Participants using interventions with ≥ 75% expected adherence were more likely to achieve treatment success, but the effects were lost once treatment stopped. Localized grade 3 or 4 erythema was reported in 62 (12%) participants (including three with dummy light). Skin thinning was reported in 13 (2·5%) participants (including one with placebo ointment). CONCLUSIONS: Combination treatment with home-based handheld NB-UVB plus TCS is likely to be superior to TCS alone for treatment of localized vitiligo. Combination treatment was relatively safe and well tolerated but was successful in only around one-quarter of participants.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Thomas KS, Batchelor JM, Akram P, et al. Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial. Br J Dermatol. 2020. PMID: 33006767. doi:10.1111/bjd.19592

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。